The Giessen-Bad Oeynhausen family study: Improved prediction of type I diabetes in a low incidence population of relatives using combinations of islet autoantibodies in a dual step model

Citation
C. Jaeger et al., The Giessen-Bad Oeynhausen family study: Improved prediction of type I diabetes in a low incidence population of relatives using combinations of islet autoantibodies in a dual step model, EXP CL E D, 107(8), 1999, pp. 496-505
Citations number
35
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
ISSN journal
09477349 → ACNP
Volume
107
Issue
8
Year of publication
1999
Pages
496 - 505
Database
ISI
SICI code
0947-7349(1999)107:8<496:TGOFSI>2.0.ZU;2-X
Abstract
To determine the value of a combined antibody screening for prediction of t ype I diabetes in a low incidence cohort, we prospectively studied 882 firs t-degree relatives (485 parents, 382 siblings and 15 offsprings) for up to Il years who were not preselected for islet cell antibody (ICA) status. Dur ing the observation period, 16 individuals developed diabetes. The first se rum sample obtained at study entry was analyzed for ICA and antibodies to i nsulin (IAA), glutamic acid decarboxylase (GADA) and anti-IA-2ic. A multiva riate analysis, according to the Cox proportional hazard model considering the joint effects of all baseline variables, selected the four antibodies a nd the specific family history as significant risk confounding factors (p < 0.05). Further analysis by Kaplan-Meier Life-table methods confirmed a sig nificantly increasing risk of diabetes with the number of autoantibodies pr esent (p < 0.001). In accordance with the Cox model, relatives with more th an one affected family member (a multiplex pedigree) and siblings and offsp rings vs, parents were at increased risk of IDDM (p < 0.05). In addition to technical problems, a screening strategy based on initial ICA testing has the potential of missing ICA negative subjects among future cases of type I diabetes (19% were ICA negative in the present study) and we therefore set out to evaluate an alternative approach using a dual step strategy with a combination of GADA and anti-IA-2ic for initial screening followed by retes ting of positive individuals for ICA and IAA. The combination of GADA and a nti-IA-2ic for primary screening (step I) proved to be more sensitive, iden tifying 94% of future cases of type I diabetes compared to 81% using ICA as initial test and this antibody combination identified 93% of those individ uals with ICA of 20 JDF or more. Retesting of positive individuals for ICA and IAA (step 2) significantly improved the positive predictive value confe ring a risk of diabetes for siblings and offsprings with more than 2 antibo dies within 5 years of 67% (95%CI: 39-90). We conclude that the prognosis o f contracting IDDM in relatives is strongly related to the number of autoan tibodies present, but the family history should be additionally considered for individual risk assessment. The proposed screening strategy could overc ome the inherent problems of the TCA and IAA assays for large-scale screeni ng. In the present study it allows 5-year risk estimates of up to 67% ident ifying 94% of future cases of type I diabetes.